Anti-BCL10 [151]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-BCL10 [151]
• Research fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
• Clone: 151
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Strain: Balb/c
• Reactivity: Human
• Host: Mouse
• Application: ELISA ; IHC ; WB
• Description: BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB.
• Immunogen: Full-length recombinant BCL-10 protein
• Isotype: IgG1 kappa
• Myeloma used: NS0

Target Details

• Target: Bcl10
• Target background: BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB.

Applications

• Application: ELISA ; IHC ; WB

Handling

• Format: Liquid
• Concentration: 0.9-1.1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Shipping at 4° C

References

• Shen et al. 2003. Blood. 102(4):1553-4. PMID: 12900354.
• Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma.
• Ye et al. 2000. Am J Pathol. 157(4):1147-54. PMID: 11021819.
• BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.
• Du et al. 2000. Blood. 95(12):3885-90. PMID: 10845924.
• BCL10 gene mutation in lymphoma.